Seagen Inc. is investigating lintuzumab (SGN-33) in combination with low dose cytarabine for the treatment of acute myeloid leukemia (AML) in older patients who have declined intensive chemotherapy. The study targets a significant patient population, particularly those over 60 years of age, who are often underrepresented in clinical trials. If successful, this combination therapy could provide a new treatment option in a market characterized by limited therapies for elderly AML patients. The competitive landscape includes other therapies targeting AML, but lintuzumab's mechanism of action as a monoclonal antibody targeting CD33 may offer a differentiated approach. Diligence should focus on the safety profile, overall survival data, and potential regulatory pathways given the unmet need in this demographic.